- Home
- QNRX
as 03-27-2025 4:00pm EST
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | KFAR SABA |
| Market Cap: | 2.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 743.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.27 - $1.57 | Next Earning Date: | 03-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Quoin Pharmaceuticals Ltd. News
QNRX Breaking Stock News: Dive into QNRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
Zacks Small Cap Research
11 days ago
QNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26
GlobeNewswire
15 days ago
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
GlobeNewswire
22 days ago
Quoin Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on Thursday, March 13, 2025
Zacks Small Cap Research
23 days ago
QNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the Disease
GlobeNewswire
24 days ago
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
GlobeNewswire
a month ago
Quoin Pharmaceuticals Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study
GlobeNewswire
a month ago
Quoin Pharmaceuticals Launches First Episode of “NETHERTON NOW” Video Series to Raise Awareness for Netherton Syndrome
Compare QNRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QNRX Quoin Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.